Medication Adherence

3
Pipeline Programs
9
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
Tacrolimus BIDPhase 3
Teva
TevaIsrael - Petach Tikva
1 program
1
Tacrolimus BIDPhase 31 trial
Active Trials
NCT02805842Unknown60Est. Aug 2018
BRAND
BRANDGermany - Wertheim
1 program
1
dolutegravir oral tablet 50mgPhase 11 trial
Active Trials
NCT04302896Completed30Est. Sep 2021
M&
Merck & Co.RAHWAY, NJ
3 programs
Comparison to peersN/A1 trial
Medication Adherence PartnerN/A1 trial
Screening and Brief InterventionN/A
Active Trials
NCT02148523Completed201Est. Jan 2015
NCT02018809Completed200Est. Jan 2015
Veloxis Pharmaceuticals
1 program
Conversion to Envarsus-XR and use of smart phone app, TransMedAxN/A1 trial
Active Trials
NCT04711291WithdrawnEst. Jul 2023
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
EMC2N/A1 trial
Active Trials
NCT03652272Completed301Est. Sep 2021
Alliance Pharmaceuticals
1 program
Screening and Brief InterventionN/A1 trial
Active Trials
NCT02604901Completed1,091Est. Jul 2014
Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
SpencerN/A1 trial
Active Trials
NCT04339296CompletedEst. Jul 2020
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
caremessageN/A1 trial
Active Trials
NCT03052231Completed80Est. Feb 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaTacrolimus BID
BRANDdolutegravir oral tablet 50mg
Catalyst PharmaceuticalsSpencer
Eli Lilly and CompanyEMC2
Veloxis PharmaceuticalsConversion to Envarsus-XR and use of smart phone app, TransMedAx
AbbViecaremessage
Merck & Co.Comparison to peers
Merck & Co.Medication Adherence Partner
Alliance PharmaceuticalsScreening and Brief Intervention

Clinical Trials (9)

Total enrollment: 1,963 patients across 9 trials

NCT02805842TevaTacrolimus BID

Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus

Start: Aug 2016Est. completion: Aug 201860 patients
Phase 3Unknown
NCT04302896BRANDdolutegravir oral tablet 50mg

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Start: Aug 2020Est. completion: Sep 202130 patients
Phase 1Completed
NCT04339296Catalyst PharmaceuticalsSpencer

Connected Healthcare for Individuals Living at Home With Chronic Conditions

Start: Mar 2019Est. completion: Jul 2020
N/ACompleted
NCT03652272Eli Lilly and CompanyEMC2

Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy

Start: Feb 2019Est. completion: Sep 2021301 patients
N/ACompleted
NCT04711291Veloxis PharmaceuticalsConversion to Envarsus-XR and use of smart phone app, TransMedAx

Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes

Start: Jun 2017Est. completion: Jul 2023
N/AWithdrawn
NCT03052231AbbViecaremessage

Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center

Start: Mar 2016Est. completion: Feb 201780 patients
N/ACompleted
NCT02148523Merck & Co.Comparison to peers

Social Forces to Improve Statin Adherence (Study B)

Start: Jan 2014Est. completion: Jan 2015201 patients
N/ACompleted
NCT02018809Merck & Co.Medication Adherence Partner

Social Forces to Improve Statin Adherence (Study A)

Start: Jan 2014Est. completion: Jan 2015200 patients
N/ACompleted
NCT02604901Alliance PharmaceuticalsScreening and Brief Intervention

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications

Start: Jun 2012Est. completion: Jul 20141,091 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space